Brickell Biotech up big on positive data on lead drug

NASDAQ:BBI   Brickell Biotech, Inc
positive data from a Japan-based Phase 3 clinical trial evaluating lead candidate topical sofpironium bromide gel, 5% in patients with primary axillary hyperhidrosis (excessive sweating on the hands, feet and underarms).

53.9% of treated patients achieved at least a 50% reduction in gravimetric sweat production and improved to a score of 1 or 2 in a scale called HDSS at the end of treatment, compared to 36.4% for vehicle

Kaken has filed a marketing application in Japan. It also has development and commercialization rights in Korea, China and certain other countries in Asia.